{"status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved.", "response": {"docs": [{"word_count": "951", "slideshow_credits": null, "multimedia": [], "news_desk": "SCI", "pub_date": "2006-04-27T07:08:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/2006/04/27/science/28askscience.html", "blog": [], "_id": "54b37adb79881019b02c254b", "headline": {"main": "Ask Science"}, "subsection_name": null, "abstract": null, "section_name": "Science", "byline": {"original": "By BENEDICT CAREY", "person": [{"rank": 1, "firstname": "Benedict", "lastname": "CAREY", "role": "reported", "organization": ""}]}, "print_page": null, "document_type": "article", "type_of_material": "News", "keywords": [{"rank": "1", "value": "Psychiatry and Psychiatrists", "name": "subject", "is_major": "N"}], "lead_paragraph": null, "snippet": null}, {"word_count": 1633, "slideshow_credits": null, "multimedia": [{"type": "image", "subtype": "thumbnail", "url": "images/2006/04/26/business/26moth_xenical.jpg", "height": 75, "legacy": {"thumbnail": "images/2006/04/26/business/26moth_xenical.jpg", "thumbnailheight": 75, "hasthumbnail": "Y"}}], "news_desk": "Business/Financial Desk", "pub_date": "2006-04-26T00:00:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/2006/04/26/business/26xenical.html", "blog": [], "_id": "4fd254898eb7c8105d7fbdba", "headline": {"main": "Hoping for a Blockbuster; Glaxo Ready to Shift Prescription Diet Pill to Over-the-Counter"}, "subsection_name": null, "abstract": null, "section_name": "Business", "byline": {"original": "By STEPHANIE SAUL", "person": [{"rank": 1, "firstname": "Stephanie", "lastname": "SAUL", "role": "reported", "organization": ""}]}, "print_page": "1", "document_type": "article", "type_of_material": "News", "keywords": [], "lead_paragraph": "When GlaxoSmithKline began talking to Roche three years ago about commercializing the prescription diet drug Xenical, the timing could not have been better for Steven L. Burton. An executive with Glaxo's consumer heath care division, Mr. Burton had been overweight for years, carrying 270 to 275 pounds on his 6-foot-1 frame. Those measurements put him well into the ''obese'' category, a condition shared by 30 percent of American adults. And his doctor had just issued a stern warning to Mr. Burton.", "snippet": "GlaxoSmithKline has tabbed Steven L. Burton to market an over-the-counter version of the diet drug Xenical, which he himself has used to lose weight."}, {"word_count": 239, "slideshow_credits": null, "multimedia": [], "news_desk": "Editorial Desk", "pub_date": "2006-04-26T00:00:00Z", "source": "The New York Times", "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9C0CE4DF133FF935A15757C0A9609C8B63", "blog": [], "_id": "4fd2aec38eb7c8105d89cf48", "headline": {"main": "Medical Marijuana, Pro and Con"}, "subsection_name": null, "abstract": "Letter from David C Leven of Compassion and Choices of New York rejects Food and Drug Administration decision indicating that medical use of marijuana is not supported by sound scientific studies; cites research (April 21 article)", "section_name": "Opinion", "byline": null, "print_page": "18", "document_type": "article", "type_of_material": "Letter", "keywords": [{"value": "LEVEN, DAVID C", "name": "persons"}, {"value": "FOOD AND DRUG ADMINISTRATION", "name": "organizations"}, {"value": "MEDICINE AND HEALTH", "name": "subject"}, {"value": "RESEARCH", "name": "subject"}, {"value": "DRUG LEGALIZATION", "name": "subject"}, {"value": "DRUG ABUSE AND TRAFFIC", "name": "subject"}, {"value": "MARIJUANA", "name": "subject"}], "lead_paragraph": "To the Editor: The decision by the Food and Drug Administration indicating that the medical use of marijuana is not supported by sound scientific studies is wrong.", "snippet": "To the Editor:      The decision by the Food and Drug Administration indicating that the medical use of marijuana is not supported by sound scientific studies is wrong."}], "meta": {"offset": 0, "hits": 3, "time": 38}}}